vs
Side-by-side financial comparison of Stoke Therapeutics, Inc. (STOK) and WESBANCO INC (WSBC). Click either name above to swap in a different company.
WESBANCO INC is the larger business by last-quarter revenue ($257.2M vs $158.6M, roughly 1.6× Stoke Therapeutics, Inc.). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs 34.5%, a 36.7% gap on every dollar of revenue.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
WesBanco, Inc., is a bank holding company headquartered in Wheeling, West Virginia, United States. It has over 200 branches in West Virginia, Ohio, Western Pennsylvania, Kentucky, Maryland, and Southern Indiana.
STOK vs WSBC — Head-to-Head
Income Statement — Q1 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $158.6M | $257.2M |
| Net Profit | $112.9M | $88.6M |
| Gross Margin | — | — |
| Operating Margin | 70.2% | — |
| Net Margin | 71.2% | 34.5% |
| Revenue YoY | 3661.1% | — |
| Net Profit YoY | 528.0% | 54.4% |
| EPS (diluted) | $1.90 | $0.88 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $257.2M | ||
| Q4 25 | — | $265.6M | ||
| Q3 25 | — | $261.6M | ||
| Q2 25 | — | $260.7M | ||
| Q1 25 | $158.6M | $193.2M | ||
| Q4 24 | $22.6M | $162.9M | ||
| Q3 24 | — | $150.8M | ||
| Q2 24 | — | $147.9M |
| Q1 26 | — | $88.6M | ||
| Q4 25 | — | $91.1M | ||
| Q3 25 | — | $83.6M | ||
| Q2 25 | — | $57.4M | ||
| Q1 25 | $112.9M | $-9.0M | ||
| Q4 24 | $-10.5M | $49.6M | ||
| Q3 24 | — | $37.3M | ||
| Q2 24 | — | $28.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 43.2% | ||
| Q3 25 | — | 39.5% | ||
| Q2 25 | — | 27.2% | ||
| Q1 25 | 70.2% | -5.0% | ||
| Q4 24 | -60.4% | 38.0% | ||
| Q3 24 | — | 29.7% | ||
| Q2 24 | — | 23.7% |
| Q1 26 | — | 34.5% | ||
| Q4 25 | — | 34.3% | ||
| Q3 25 | — | 31.9% | ||
| Q2 25 | — | 22.0% | ||
| Q1 25 | 71.2% | -4.7% | ||
| Q4 24 | -46.4% | 30.5% | ||
| Q3 24 | — | 24.7% | ||
| Q2 24 | — | 19.5% |
| Q1 26 | — | $0.88 | ||
| Q4 25 | — | $0.97 | ||
| Q3 25 | — | $0.84 | ||
| Q2 25 | — | $0.57 | ||
| Q1 25 | $1.90 | $-0.15 | ||
| Q4 24 | $-0.15 | $0.72 | ||
| Q3 24 | — | $0.54 | ||
| Q2 24 | — | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $274.8M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $350.1M | $4.1B |
| Total Assets | $406.9M | $27.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $956.1M | ||
| Q3 25 | — | $1.0B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | $274.8M | $1.1B | ||
| Q4 24 | $128.0M | $568.1M | ||
| Q3 24 | — | $620.9M | ||
| Q2 24 | — | $486.8M |
| Q1 26 | — | $4.1B | ||
| Q4 25 | — | $4.0B | ||
| Q3 25 | — | $4.1B | ||
| Q2 25 | — | $3.8B | ||
| Q1 25 | $350.1M | $3.8B | ||
| Q4 24 | $229.0M | $2.8B | ||
| Q3 24 | — | $2.8B | ||
| Q2 24 | — | $2.5B |
| Q1 26 | — | $27.5B | ||
| Q4 25 | — | $27.7B | ||
| Q3 25 | — | $27.5B | ||
| Q2 25 | — | $27.6B | ||
| Q1 25 | $406.9M | $27.4B | ||
| Q4 24 | $271.6M | $18.7B | ||
| Q3 24 | — | $18.5B | ||
| Q2 24 | — | $18.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $131.8M | — |
| Free Cash FlowOCF − Capex | $131.7M | — |
| FCF MarginFCF / Revenue | 83.0% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | 1.17× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $290.4M | ||
| Q3 25 | — | $116.9M | ||
| Q2 25 | — | $105.0M | ||
| Q1 25 | $131.8M | $-26.4M | ||
| Q4 24 | $-23.2M | $211.0M | ||
| Q3 24 | — | $60.7M | ||
| Q2 24 | — | $18.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $280.0M | ||
| Q3 25 | — | $114.9M | ||
| Q2 25 | — | $98.3M | ||
| Q1 25 | $131.7M | $-30.7M | ||
| Q4 24 | $-23.2M | $200.7M | ||
| Q3 24 | — | $56.9M | ||
| Q2 24 | — | $17.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | 105.4% | ||
| Q3 25 | — | 43.9% | ||
| Q2 25 | — | 37.7% | ||
| Q1 25 | 83.0% | -15.9% | ||
| Q4 24 | -102.7% | 123.2% | ||
| Q3 24 | — | 37.7% | ||
| Q2 24 | — | 11.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.9% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | 0.1% | 2.2% | ||
| Q4 24 | 0.2% | 6.3% | ||
| Q3 24 | — | 2.5% | ||
| Q2 24 | — | 0.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.19× | ||
| Q3 25 | — | 1.40× | ||
| Q2 25 | — | 1.83× | ||
| Q1 25 | 1.17× | — | ||
| Q4 24 | — | 4.25× | ||
| Q3 24 | — | 1.63× | ||
| Q2 24 | — | 0.63× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
STOK
Segment breakdown not available.
WSBC
| Net Interest Income | $215.4M | 84% |
| Noninterest Income | $41.8M | 16% |
